An adherence based cost–consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%

References

• Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85
   PubMed Web of Science ®Google Scholar
• Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 2011;152:515-22
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Diabetic Retinopathy, 4th printing 2012 edn. San Francisco, CA: American Academy of Ophthalmology, 2008
   Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure–lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• McKee HD, Gupta MS, Ahad MA, et al. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye (London, England) 2005;19:923-4
   PubMed Web of Science ®Google Scholar
• Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-71 e1
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence 2011;5:441-63
   PubMed Web of Science ®Google Scholar
• Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Experiment Ophthalmology 2007;35:602-11
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
   PubMed Web of Science ®Google Scholar
• Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009;12:489-97
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 2008;115:1123-9
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology 2011;118:2398-402
   PubMed Web of Science ®Google Scholar
• Kooner KS, AlBdoor M, Cho BJ, et al. Risk factors for progression to blindness in high tension primary open angle glaucoma: Comparison of blind and nonblind subjects. Clin Ophthalmol 2008;2:757-62
   PubMedGoogle Scholar
• Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003;110:726-33
   PubMed Web of Science ®Google Scholar
• Campbell J, Schwartz G, LaBounty B, et al. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Curr Med Res Opin 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Stein JD, Kim DD, Peck WW, et al. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol 2012;130:497-505
   PubMed Web of Science ®Google Scholar
• Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009;116:823-32
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008;126:1030-6
   PubMed Web of Science ®Google Scholar
• Lee PP, Kelly SP, Mills RP, et al. Glaucoma in the United States and Europe: predicting costs and surgical rates based upon stage of disease. J Glaucoma 2007;16:471-8
   PubMed Web of Science ®Google Scholar
• Pasquale LR, Dolgitser M, Wentzloff JN, et al. Health care charges for patients with ocular hypertension or primary open-angle glaucoma. Ophthalmology 2008;115:633-8 e4
   PubMed Web of Science ®Google Scholar
• Berenson K, Kymes S, Walt JG, et al. The relationship of mean deviation scores and resource utilization among patients with glaucoma: a retrospective United States and European chart review analysis. J Glaucoma 2009;18:390-4
   PubMed Web of Science ®Google Scholar
• Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60
   PubMed Web of Science ®Google Scholar
• Deva NC, Insull E, Gamble G, et al. Risk factors for first presentation of glaucoma with significant visual field loss. Clin Experiment Ophthalmol 2008;36:217-21
   PubMed Web of Science ®Google Scholar
• de Silva SR, Riaz Y, Purbrick RM, et al. There is a trend for the diagnosis of glaucoma to be made at an earlier stage in 2010 compared to 2008 in Oxford, United Kingdom. Ophthalmic Physiol Opt 2013;33:179-82
   PubMed Web of Science ®Google Scholar
• NVSR. United States Life Tables, 2007. NVSR 599. 61 pp. (PHS) 2011-1120. 2007
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Clinical Guideline 85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. In: NICE (ed.) London, 2009. Available at: http://guidance.nice.org.uk/CG85/NICEGuidance/pdf/English [Last accessed June 2013]
   Google Scholar
• Hodapp E, Parrish RG, Anderson DR. Clinical decisions in glaucoma. St Louis: Mosby, 1993 . Available at: http://guidance.nice.org.uk/CG85/NICEGuidance/pdf/English
   Google Scholar
• Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007;48:5052-7
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Platt R, Reardon G, et al. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007;114:648-52
   PubMed Web of Science ®Google Scholar
• CMS. Medicare Health & Drug Plan Quality and Performance Ratings 2012 Part C & Part D Technical Notes. 2011. Available at: http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/PerformanceData.html [Last accessed June 2013]
   Google Scholar
• Nau DP and Pharmacy Quality Alliance. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. 2013. Available at: http://pqaalliance.org/resources/adherence.asp [Last accessed June 2013]
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Heijl A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology 2009;116:2271-6
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 2003;81:286-93
   PubMedGoogle Scholar
• Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 2010;128:1249-55
   PubMed Web of Science ®Google Scholar
• Bramley T, Peeples P, Walt JG, et al. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol 2008;126:849-56
   PubMed Web of Science ®Google Scholar
• Bureau of Labor and Statistics – Consumer Price Index. 2012. Available at: www.bls.gov [Last accessed June 2013]
   Google Scholar
• Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-17
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004;138:458-67
   PubMed Web of Science ®Google Scholar